Abcellera Biologics Inc (ABCL)

$8.11 +0.51 (6.71%)
Market Cap 2.32B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 8,464,199
Avg Vol 8,686,430
Day's Range N/A - N/A
Shares Out 305.38M
Stochastic %K 89%
Beta 1.14
Analysts Strong Sell
Price Target $10.43

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
Stocktradesmoon
Stocktradesmoon Jul. 3 at 6:45 PM
$ABCL $ABCL (weekly) it did a 3x since Feb and after having smashed the $7 target is now headed to the $10 .. add on pullbacks
0 · Reply
BiobankerPhD
BiobankerPhD Jul. 3 at 2:34 PM
$ABCL Anybody else notice that Abdera Therapeutics (who Abcellera own an equity stake) appears to have quietly shut down? The Abdera website has disappeared and they auctioning off all the lab equipment
3 · Reply
MrHurts
MrHurts Jul. 3 at 1:46 PM
$ABCL This is how generational wealth is made
0 · Reply
snowPOW
snowPOW Jul. 3 at 1:51 AM
$ABCL this one could be a millionaire maker! I like it!
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Jul. 3 at 12:18 AM
$ABCL Bull flag at end of day end of week 3 day weekend. Not bad.
0 · Reply
MorganHoratio
MorganHoratio Jul. 2 at 11:29 PM
One of the strongest sectors outside of AI right now is Biotech. Drug Discovery $TWST Twist Bioscience $ABSI Absci $RXRX Recursion $ABCL AbCellera $NRIX Nurix Therapeutics Smart money is pivoting to the ultimate AI crossover: Drug Discovery & TechBio! This sector captures AI’s efficiency boom without the tech sector’s valuation bubble. DNA giant TWST is absolutely ripping, up over 200% this year to fresh historical highs on strong revenue growth. Protein degradation leader NRIX also just smashed 52-week highs. Alongside Nvidia-backed RXRX, ABSI, and ABCL, this sector is using AI algorithms to shatter traditional pharma limits. Can AI Biotech outpace pure tech in H2? Which ticker is your top play: TWST, ABSI, RXRX, ABCL, or NRIX? Drop your picks below! 👇
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 2 at 9:20 PM
$ABCL Weekly close over $8
0 · Reply
PLTRLONGDONG
PLTRLONGDONG Jul. 2 at 8:56 PM
$ABCL you would be crazy to sell before IPO price
2 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 2 at 8:10 PM
$ABCL $ABCL to $25+ EOY. That is all
1 · Reply
Buying_Low_Selling_High
Buying_Low_Selling_High Jul. 2 at 8:02 PM
$ABCL Great price action heading into the weekend.
0 · Reply
Latest News on ABCL
Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

Jun 17, 2026, 7:43 AM EDT - 16 days ago

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

JAZZ

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

Jun 17, 2026, 7:00 AM EDT - 16 days ago

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

AbCellera appoints Victor Sandor to board of directors

2026-06-05T13:05:56.000Z - 4 weeks ago

AbCellera appoints Victor Sandor to board of directors

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 5, 2026, 9:00 AM EDT - 4 weeks ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 11:40 AM EDT - 4 weeks ago

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 8:00 PM EDT - 7 weeks ago

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 7 weeks ago

AbCellera price target raised to $8 from $7 at Stifel

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 7 weeks ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 7 weeks ago

AbCellera Biologics Earnings release: Q1 2026

AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 7 weeks ago

AbCellera Biologics Quarterly report: Q1 2026

AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 7 weeks ago

AbCellera Biologics Slides: Q1 2026

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 11, 2026, 4:05 PM EDT - 7 weeks ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

May 7, 2026, 4:05 PM EDT - 2 months ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera initiated with an Overweight at Cantor Fitzgerald

2026-05-05T10:36:31.000Z - 2 months ago

AbCellera initiated with an Overweight at Cantor Fitzgerald

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

AbCellera Biologics Proxy statement: Proxy filing

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

AbCellera Biologics Proxy statement: Proxy filing

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 21, 2026, 1:30 PM EDT - 2 months ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Apr 20, 2026, 9:00 AM EDT - 2 months ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera initiated with a Buy at JonesResearch

2026-04-09T20:10:26.000Z - 3 months ago

AbCellera initiated with a Buy at JonesResearch

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Apr 1, 2026, 4:05 PM EDT - 3 months ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 17, 2026, 4:30 PM EDT - 3 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 9:50 AM EST - 4 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Annual report: Q4 2025

AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Earnings release: Q4 2025

AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Slides: Q4 2025

AbCellera reports FY25 EPS (49c) vs. (55c) last year

2026-02-24T21:15:21.000Z - 4 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year

AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 4 months ago

AbCellera Reports Full Year 2025 Business Results

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Feb 11, 2026, 4:05 PM EST - 5 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 22, 2026, 4:05 PM EST - 5 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:45 PM EST - 6 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 6 months ago

AbCellera Biologics Slides: Corporate presentation

AbCellera doses first patients in Phase 2 portion of ABCL635 trial

2026-01-12T14:36:23.000Z - 6 months ago

AbCellera doses first patients in Phase 2 portion of ABCL635 trial

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Jan 12, 2026, 9:00 AM EST - 6 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera to receive $36M upfront in patent litigation settlement with Bruker

2025-12-18T14:20:19.000Z - 7 months ago

AbCellera to receive $36M upfront in patent litigation settlement with Bruker

BRKR

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 18, 2025, 9:00 AM EST - 7 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 4:05 PM EST - 7 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 8:00 AM EST - 7 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 8 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 8 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera downgraded to Market Perform from Outperform at Leerink

2025-11-07T11:16:20.000Z - 8 months ago

AbCellera downgraded to Market Perform from Outperform at Leerink

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Quarterly report: Q3 2025

AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Earnings release: Q3 2025

AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Slides: Q3 2025

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 8 months ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 9 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 9 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera appoints Sarah Noonberg as Chief Medical Officer

2025-09-10T13:20:54.000Z - 10 months ago

AbCellera appoints Sarah Noonberg as Chief Medical Officer

MGX

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 10 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 5, 2025, 9:30 AM EDT - 10 months ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 11 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Quarterly report: Q2 2025

AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Earnings release: Q2 2025

AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Slides: Q2 2025

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 11 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025

AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025

AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024

AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024

AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024

AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024

AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera Biologics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 11:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

AbCellera Biologics Transcript: 2024 Wells Fargo Healthcare Conference

Sep 5, 2024, 3:00 PM EDT - 1 year ago

AbCellera Biologics Transcript: 2024 Wells Fargo Healthcare Conference

AbCellera to Present at Upcoming Investor Conferences in September

Aug 29, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at Upcoming Investor Conferences in September

AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q2 2024

AbCellera Biologics Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q2 2024

AbCellera Biologics Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q2 2024

AbCellera Biologics Slides: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q2 2024

AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q2 2024 Business Results

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jul 31, 2024, 9:00 AM EDT - 2 years ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 25, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

AbCellera Biologics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 10, 2024, 3:20 PM EDT - 2 years ago

AbCellera Biologics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 28, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024

AbCellera Biologics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q1 2024

AbCellera Biologics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q1 2024

AbCellera Biologics Slides: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q1 2024

AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

May 1, 2024, 9:00 AM EDT - 2 years ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference

Apr 16, 2024, 10:00 AM EDT - 2 years ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 8, 2024, 12:05 PM EDT - 2 years ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 3, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Stocktradesmoon
Stocktradesmoon Jul. 3 at 6:45 PM
$ABCL $ABCL (weekly) it did a 3x since Feb and after having smashed the $7 target is now headed to the $10 .. add on pullbacks
0 · Reply
BiobankerPhD
BiobankerPhD Jul. 3 at 2:34 PM
$ABCL Anybody else notice that Abdera Therapeutics (who Abcellera own an equity stake) appears to have quietly shut down? The Abdera website has disappeared and they auctioning off all the lab equipment
3 · Reply
MrHurts
MrHurts Jul. 3 at 1:46 PM
$ABCL This is how generational wealth is made
0 · Reply
snowPOW
snowPOW Jul. 3 at 1:51 AM
$ABCL this one could be a millionaire maker! I like it!
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Jul. 3 at 12:18 AM
$ABCL Bull flag at end of day end of week 3 day weekend. Not bad.
0 · Reply
MorganHoratio
MorganHoratio Jul. 2 at 11:29 PM
One of the strongest sectors outside of AI right now is Biotech. Drug Discovery $TWST Twist Bioscience $ABSI Absci $RXRX Recursion $ABCL AbCellera $NRIX Nurix Therapeutics Smart money is pivoting to the ultimate AI crossover: Drug Discovery & TechBio! This sector captures AI’s efficiency boom without the tech sector’s valuation bubble. DNA giant TWST is absolutely ripping, up over 200% this year to fresh historical highs on strong revenue growth. Protein degradation leader NRIX also just smashed 52-week highs. Alongside Nvidia-backed RXRX, ABSI, and ABCL, this sector is using AI algorithms to shatter traditional pharma limits. Can AI Biotech outpace pure tech in H2? Which ticker is your top play: TWST, ABSI, RXRX, ABCL, or NRIX? Drop your picks below! 👇
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 2 at 9:20 PM
$ABCL Weekly close over $8
0 · Reply
PLTRLONGDONG
PLTRLONGDONG Jul. 2 at 8:56 PM
$ABCL you would be crazy to sell before IPO price
2 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 2 at 8:10 PM
$ABCL $ABCL to $25+ EOY. That is all
1 · Reply
Buying_Low_Selling_High
Buying_Low_Selling_High Jul. 2 at 8:02 PM
$ABCL Great price action heading into the weekend.
0 · Reply
Cryptocr7
Cryptocr7 Jul. 2 at 8:00 PM
$ABCL nice close
1 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 2 at 6:05 PM
$ABCL The strength of $ABCL in a red market with minimal volume is giving me hope that something big is about to happen 👀😉
1 · Reply
tranq19
tranq19 Jul. 2 at 5:56 PM
$ABCL august maybe, or with earnings first week or so of August? Some sites showing not recruiting
3 · Reply
The_Blunderer
The_Blunderer Jul. 2 at 4:43 PM
$ABCL I just bought some shares. Looks like a winner in the (near) future
0 · Reply
PaloPB
PaloPB Jul. 2 at 3:35 PM
$ABCL ,📈✅
1 · Reply
Ckkung71
Ckkung71 Jul. 2 at 3:22 PM
$ABCL Best thing to do right now is just sit on your shares don’t let them fool you with all trapps..
1 · Reply
DeMampCamp
DeMampCamp Jul. 2 at 2:22 PM
$ABCL You can't hide $10, we see you in our sights :)
0 · Reply
Odoji
Odoji Jul. 2 at 2:19 PM
$ABCL 💉
0 · Reply
Kylenorth
Kylenorth Jul. 2 at 2:18 PM
$ABCL BO coming!! thanks for leaving Niel
0 · Reply
Arnoldsens
Arnoldsens Jul. 2 at 2:17 PM
$ABCL This will be above 10 by the middle of next week if all goes well in the world.
0 · Reply
KryptonResearch
KryptonResearch Jul. 2 at 2:14 PM
AI-enabled healthcare/research is the most obvious massive winner… $ABCL $SLS $RXRX $IBRX $TEM etc… We take a look at a lesser known name in this space, with similar, if not greater upside potential given their ownership of the data layer. This is the next big sector, we have our pick, but there are so many names that will pay well. https://kryptonresearch.substack.com/p/blood-money
1 · Reply
TheDrunkTrader69
TheDrunkTrader69 Jul. 2 at 2:12 PM
$ABCL Dip N Rip just like I said.
0 · Reply